Nektar Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NKTR and other ETFs, options, and stocks.

About NKTR

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit.

CEO

Howard W. Robin

CEOHoward W. Robin

Employees

Employees61

Headquarters

San Francisco, California

HeadquartersSan Francisco, California

Founded

1990

Founded1990

Employees

Employees61

NKTR Key Statistics

Market cap

1.07B

Market cap1.07B

Price-Earnings ratio

-6.55

Price-Earnings ratio-6.55

Dividend yield

—

Dividend yield—

Average volume

706.49K

Average volume706.49K

High today

$59.90

High today$59.90

Low today

$56.10

Low today$56.10

Open price

$57.99

Open price$57.99

Volume

472.14K

Volume472.14K

52 Week high

$62.95

52 Week high$62.95

52 Week low

$6.48

52 Week low$6.48

NKTR News

Simply Wall St 2d

How Investors Are Reacting To Nektar Therapeutics Securing FDA Fast Track For Eczema Drug Candidate

In recent news, Nektar Therapeutics announced that its lead candidate, rezpegaldesleukin, received Fast Track Designation from the FDA following strong performa...

Nasdaq 2d

This Stock Is Up By 285% This Year But Could Still Jump By 53%, According to Wall Street

Key Points Nektar Therapeutics' leading candidate is performing well so far in phase 2 studies. This medicine could disrupt the large and competitive eczema t...

Analyst ratings

75%

of 8 ratings

Buy

75%

Hold

12.5%

Sell

12.5%

People also own

Based on the portfolios of people who own NKTR. This list is generated using Robinhood data, and it’s not a recommendation.